Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Judy D. Olian

At a glance: Judy D. Olian is Director at UNITED THERAPEUTICS (UTHR). Their latest SEC Form 4, filed Mar 24, 2026, reported a sale of $106K. On file: 1 purchase line ($60K) and 4 sale lines ($417K).

Disclosed holdings: about $2.4M of UTHR stock: 4,245 shares reported on their latest Form 4 (filed Mar 24, 2026), valued at the Nov 19, 2026 close of $563.33. This counts only UTHR shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

Director at Ares Management Corp (ARES); Director at UNITED THERAPEUTICS Corp (UTHR)

Purchase track record

Not enough history. Based on 1 purchase with a full 90 days of price history.

—
Avg. 90-day return+8.4%
vs. S&P 500-1.1%
Beat the market0%
Paper profit on buys−$170
Total bought / sold$60K / $417K

Judy D. Olian's InsiderPrint

5 trades from SEC Form 4 filings, 2026 to 2026, drawn as one fingerprint.

InsiderPrint of Judy D. Olian: 5 trades, 2026 to 20262026: 1 buy, 4 sales

Reading this print: Mostly sells, trading about 5 times a year, typically $102K a trade; most sales are on a pre-planned 10b5-1 schedule.

  • Bump outward: a purchase (1)
  • Dent inward: a sale (4)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. Alan EzekowitzDirector · FULC · 99% match
  2. Michael DastoorCEO · JBL · 98% match
  3. Jennifer JarrettCEO, President · DMRA · 97% match
  4. James C. Fish Jr.Director · CAT · 96% match
  5. William B. CyrCEO · FRPT · 95% match

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Every purchase since 2026

From the SEC's insider data sets: each open-market buy by Judy D. Olian, matched to how the stock did over the next 90 days against the S&P 500.

0 of 1 buy beat the S&P 500 (0%), median -1.1% vs. the index. Small sample: treat with care. All insider buys: 46%.

StockFiled90 days vs. S&P 500
ARESFeb 24, 2026-1.1%

Buys made close together in one stock count once. Price-only returns; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Mar 24SEC UTHRUNITED THERAPEUTICS Corp Sell Plan 2004,245 held (−4%) $530.00 $106K +6.3%
Mar 16SEC UTHRUNITED THERAPEUTICS Corp Sell Plan 2004,445 held (−4%) $535.44 $107K +5.2%
Mar 9SEC UTHRUNITED THERAPEUTICS Corp Sell Plan 2004,645 held (−4%) $510.00 $102K +10.5%
Mar 2SEC UTHRUNITED THERAPEUTICS Corp Sell Plan 2004,845 held (−4%) $509.55 $102K +10.6%
Feb 24SEC ARESAres Management CorpFirst buy Buy 48029,734 held (+2%) $124.43 $60K -0.3%
  • Sell

    Director Judy D. Olian sold $106K of UTHR at $530.00 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Judy D. Olian sold $107K of UTHR at $535.44 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Judy D. Olian sold $102K of UTHR at $510.00 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Judy D. Olian sold $102K of UTHR at $509.55 — pre-scheduled 10b5-1 plan sale.

  • Buy

    Director Judy D. Olian bought $60K of ARES at $124.43 — first open-market purchase in our records.

Follow Judy D. Olian

Get one email when Judy D. Olian files a new purchase or sale. Free.

At most one email a day about Judy D. Olian, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.